Evidence map›Paper›PMID 40905157›Full record

ArticleHistology and histopathology2026

Long non-coding RNA C20orf56 as a predictor of response to neoadjuvant CCRT and survival rates of rectal cancers.

Chih-I Chen, Cheng-Fa Yeh, Ching-Chieh Yang, Yi-Kai Kao, Pin-Chun Chen, Po-Wen Yang, Sung-Wei Lee, Yu-Feng Tian, Yu-Hsuan Kuo, Li-Ching Wu and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chih-I Chen *Division of Colon and Rectal Surgery, Department of Surgery, E-DA Hospital, Kaohsiung, Taiwan.
Cheng-Fa Yeh *Division of General Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Ching-Chieh YangDepartment of Radiation Oncology, Chi Mei Medical Center, Tainan, Taiwan.
Yi-Kai KaoDivision of Colon and Rectal Surgery, Department of Surgery, E-DA Hospital, Kaohsiung, Taiwan.
Pin-Chun ChenDivision of Colon and Rectal Surgery, Department of Surgery, E-DA Hospital, Kaohsiung, Taiwan.
Po-Wen YangDivision of Colon and Rectal Surgery, Department of Surgery, E-DA Hospital, Kaohsiung, Taiwan.
Sung-Wei LeeDepartment of Radiation Oncology, Chi Mei Medical Center, Liouying, Taiwan.
Yu-Feng TianDivision of Colon and Rectal Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
Yu-Hsuan KuoDivision of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Li-Ching WuInstitute of Biomedical Science, National Sun Yat-Sen University, Kaohsiung, Taiwan.
Chien-Feng LiTrans-Omic Laboratory for Precision Medicine, Precision Medicine Center, Chi Mei Medical Center, Tainan, Taiwan.
Yi-Che Chang ChienDepartment of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
I-Wei ChangDepartment of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

Funding

Chi Mei Medical Center and Taipei Medical University 113CM-TMU-11
6 · The paper itself

Abstract

introductionColorectal cancer is the third most prevalent malignancy and the second leading cause of cancer mortality worldwide. Neoadjuvant concurrent chemoradiotherapy (CCRT) improves survival and increases curative surgery rates in rectal cancer. C20orf56, a long non-coding RNA (lncRNA), plays diverse roles in cancer, but its association with neoadjuvant CCRT response and prognosis in rectal cancer remains unexplored. MATERIALS AND

methodsTumor samples from 343 rectal cancer patients who received neoadjuvant CCRT followed by surgery were analyzed for C20orf56 expression via

resultsA transcriptomic analysis (GSE35452) identified C20orf56 as differentially expressed between responders and non-responders. Decreased expression of C20orf56 showed significant correlations with less advanced post-treatment tumor invasiveness, negative post-treatment nodal metastasis, absence of vascular invasion and perineural invasion, and improved response to neoadjuvant CCRT (all

conclusionC20orf56 may play a significant role in rectal cancer progression and response to neoadjuvant CCRT, serving as a novel prognostic factor.

Indexed as

Biomarkers, TumorRectal NeoplasmsRNA, Long NoncodingAdultAgedChemoradiotherapyFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoadjuvant TherapyPrognosisSurvival RateTreatment OutcomeBiomarkers, TumorRNA, Long Noncoding

Identifiers

PMID40905157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.